UPCI Hillman Cancer Center
Welcome,         Profile    Billing    Logout  
 13 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tarhini, Ahmad
E1609, NCT01274338 / 2011-004257-29: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Checkmark From E1609 study for resected high-risk melanoma
Mar 2020 - Mar 2020: From E1609 study for resected high-risk melanoma
Checkmark Data from P3 study of adjuvant ipilimumab vs. high-dose interferon alfa-2b for resected high-risk melanoma
Dec 2019 - Dec 2019: Data from P3 study of adjuvant ipilimumab vs. high-dose interferon alfa-2b for resected high-risk melanoma
Checkmark From 029 study for melanoma at ASCO 2014
More
Active, not recruiting
3
1673
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI), Bristol-Myers Squibb, National Cancer Institute
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/19
03/25
NCT02339571: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting
2/3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Elastography, MRE, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
06/33
06/33
E3611, NCT01708941: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Active, not recruiting
2
88
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
08/17
03/25
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
06/28
06/28
NCT04869137: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Active, not recruiting
2
26
US
Lenvatinib Oral Product, LENVIMA, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
09/25
09/26
NCT06295159: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting
2
90
US
Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Ipilimumab, Yervoy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
07/27
07/27
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
08/25
11/29
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq
H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc.
Metastatic Uveal Melanoma
09/25
12/25
NCT04708418: A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Active, not recruiting
2
60
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, VLP-encapsulated TLR9 Agonist CMP-001
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
06/25
06/25
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Recruiting
2
37
US
Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Uveal Melanoma, Ocular Melanoma
07/26
07/26
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
KEYNOTE-E64, NCT04787042: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Recruiting
1/2
316
US
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA®
Simcha IL-18, Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
06/25
12/25
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT05358938: Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Active, not recruiting
1
22
US
Exercise, Checkpoint Blockade, Immune, Avelumab, Cemiplimab, Ipilimumab, Nivolumab, Pembrolizumab
H. Lee Moffitt Cancer Center and Research Institute
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
10/24
12/25
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
1
30
US
Cemiplimab-Rwlc, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
06/27
06/27
NCT03114319: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Active, not recruiting
1
227
Europe, Canada, Japan, US, RoW
TNO155, TNO155 in combination with EGF816 (nazartinib)
Novartis Pharmaceuticals
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma
05/25
05/25
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Terminated
1
45
US
KD033 (SAR445710)
Kadmon, a Sanofi Company
Solid Tumor
12/23
12/23
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Recruiting
1
50
US
Encorafenib Pill, Binimetinib Pill, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
01/25
01/26
NCT05651828: Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Recruiting
1
34
US
Vismodegib 150 MG Oral Capsule, Erivedge
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
Advanced Basal Cell Carcinoma
12/28
12/29

Download Options